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ABSTRACT 
Recent research suggests that the development of behavioral sensitization to 
cocaine may be mediated by the repeated stimulation of either DI-type or D2-type 
dopamine receptors. The purpose of the present study was to test this hypothesis by 
determining whether concurrent treatments with a DI-type dopamine antagonist (SCH 
23390) and a D2-type dopamine antagonist (eticlopride) combined would prevent the 
development ofbehavioral sensitization to cocaine. 
Forty-eight male Wistar rats, that weighed between 200 and 250g were 
injected daily for four days with one of the following drug combinations: 
vehicle/vehicle, vehicle/cocaine (ISmg/kg), SCH 23390 (O. lmg/kg)/eticlopride 
(O. lmg/kg)/vehicle, or SCH 23390/eticlopride/cocaine. Each rat was first injected 
S.C. with either a combination of SCH 23390 and eticlopride or vehicle, and then 25 
min later, each rat was injected I.P. with either cocaine or vehicle. Five min after the 
second injection, each rat was tested for locomotor activity in photocell activity boxes 
(Med-Associates) for 60 min. On day five, all rats were tested for activity after a 
challenge injection of cocaine (10 mg/kg) alone. 
The major findings were as follows: a) rats treated with cocaine alone were 
significantly more active during the pretreatment phase than rats treated with only 
vehicle; b) combined SCH 23390/eticlopride treatments produced a significant 
suppression of activity on all test days, and completely blocked the acute activating 
effects of cocaine; c) rats pretreated with cocaine displayed a greater activity response 
to the challenge injection of cocaine on day five than did rats pretreated with only 
vehicle (i.e., sensitization); d) concurrent pretreatment with the antagonist 
combination did not block the development of behavioral sensitization to cocaine; and 
e) pretreatment with the antagonist combination alone increased subsequent sensitivity 
to cocaine. 
Consistent with previous research, repeated cocaine treatments resulted in the 
development of behavioral sensitization. Although the antagonist combination 
completely blocked the acute locomotor-activating effects of cocaine, pretreatment 
with the antagonist combination did not block the development of behavioral 
sensitization to cocaine. These findings suggest that the repeated stimulation of 
dopamine receptors is not necessary for the development of cocaine-induced 
behavioral sensitization. 
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I. PsychostimulantDrugs and Behavioral Sensitization: 
Drugs of abuse have become a increasing concern in our society. One category of 
drugs that receives a great deal of attention is that ofpsychostimulants. Today, 
stimulant drugs such as amphetamine and cocaine remain among the most widely 
abused of the many psychoactive compounds available (Robinson & Becker, 1986, 
Kalivas & Stewart, 1991; Stewart & Baldiani, 1993). When taken acutely, 
psychostimulants induce euphoria and heightened arousal, but after chronic use a 
variety of behavioral disorders may develop. Initially, psychostimulant abuse may 
result in craving, and a supersensitivity to other psychostimulants. With repeated self-
administration, a pattern of compulsive drug-seeking and drug-taking behavior often 
occurs (Robinson & Berridge, 1993; Robinson & Becker, 1986; Berridge & Robinson, 
1995). In addition, when repeatedly, or chronically administered, various behavioral 
disorders may result. Such disorders include panic attacks, delirium, and 
schizophrenic-like psychoses (Robinson & Becker, 1986, Robinson & Berridge,1993; 
Kalivas & Stewart, 1991). Although these disorders may subside if drug use is 
discontinued, they have been shown to resurface as many as ten years later if drug use 
is reinstated (Kalivas et al,1991; Ellinwood, 1967; Kramer, Fischman, & Littlefield, 
1967). Thus, it is apparent that after chronic use of psychomotor stimulants, 
long lasting alterations in the central nervous system occur (Mattingly, Gotsick & 
Salmanca, 1988). 
Repeated psychomotor stimulant treatment in animals produces behavioral 
sensiti_zation (Kalivas & Stewart, 1991; Robinson & Becker, 1986; Segal, 1975). 
Behavioral sensitization is said to occur when the same dose of a drug, repeatedly 
administered, produces a progressively greater behavioral effect. Once established, 
this behavioral supersensitivity is persistent for weeks or even months (Browne & 
Segal, 1977; Peris & Zahniser, 1987). For example, when rats are initially injected 
with cocaine, a modest increase in locomotor activity is usually elicited. After 
repeated treatments, however, the same dose of cocaine produces a significantly 
greater hyperactivity response (Angrist, 1983; Mattingly, Hart, Lim, & Perkins, 1994; 
Segal & Schuckit, 1983). In addition, recent evidence suggests that the rewarding 
effects of psychostimulant drugs may also become sensitized with repeated drug 
administrations (Lett 1989; Pierre & Vezina, 1997). 
2 
Neurobiological changes that mediate behavioral sensitization in rats are widely 
thought to be the same as those that produce the behavioral disorders associated with 
psychostimulant abuse in humans (Kalivas & Stewart, 1991; Robinson & Becker, 
1986). In addition, these neurobiological changes may also be responsible for the 
intense craving and compulsive drug-seeking behavior that develops in humans after 
chronic psychostimulant abuse (Robinson & Berridge, I 993). Consequently, current 
research is seeking to determine the neurobiological mechanisms which mediate the 
development and persistence of behavioral sensitization. 
II. Dopamine Receptors and Dopamine Mediation of Behavioral Sensitization: 
The rewarding and activating effects of psychostimulant drugs appear to be 
mediated by the dopaminergic neurotransmitter system (Wise & Bozarth, 1985; Wise 
& Bozarth, 1987). Psychostimulant drugs act to block the re-uptake and /or promote 
the release of dopamine into the synaptic cleft, and this action in forebrain dopamine 
terminal fields is thought to mediate much of the acute locomotor stimulant effect of 
these drugs (Kalivas & Stewart, 1991). The dopamine neurons of primary interest in 
the study of behavioral sensitization are located in the ventral tegmentum of the 
mesencephalon and were originally categorized as the A9 and Al O cell clusters. The 
Al O region is localized predominantly to the ventral tegmental area, and projects to 
the structures closely associated with the limbic system, most prominently the 
ventromedial portion of the striatal complex referred to as the nucleus accumbens, but 
also the olfactory tubercle, septa! nucleus, and other limbic related areas (White, 
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1996). This system is considered separate from the nigrostriatal dopamine system in 
which the dopamine cell bodies in the A9 region are localized almost exclusively to the 
substantia nigra pars compacta, which projects to the neostriatum (Kalivas & Stewart, 
1991). 
The acute motor stimulant effects of psychostimulant drugs such as 
amphetamine and cocaine are believed to result from activation of the mesolimbic 
dopamine system which arises from Al O dopamine neurons to innervate the nucleus 
accumbens and other limbic brain structures (Steketee, Striplin, Murray, & Kalivas 
1990). Despite the overlapping anatomy of the nigrostriatal and mesolimbic dopamine 
systems, each system appears to subserve distinct aspects of behavior. Current 
research has indicated that the nigrostriatal dopamine system facilitates motor 
preparatory processes and also stereotypic behaviors in rats. In contrast, the 
mesolimbic dopamine system facilitates the impact of stimulus-reward associations on 
behavior involved in incentive motivational processes, drug abuse, and craving 
(Robinson & Berridge, 1993; White 1996). 
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Recent advances in molecular biology have revealed multiple dopamine 
receptor subtypes (Civelli, Bunzow, & Grandy, 1993; Gingrich & Caron, 1993). 
Researchers have now distinguished five distinct subtypes of dopamine receptors. 
These five subtypes, however, can be divided into two families based upon molecular, 
biochemical, and pharmacological properties. The D 1 and DS receptor subtypes are 
alike in that they are found post-synaptically and stimulate adenlate cyclase enzyme 
activity. The D2 subfamily includes the D2, D3, and D4 receptor subtypes. The D2, 
D3, and D4 subtypes are similar in that they are located both pre- and post-
synaptically and are either unlinked or inhibit the adenlate cyclase enzyme (Schwartz, 
Giros, Martres, & Sokoloff, 1992). Due to the similarities of these receptor subtypes, 
DI or D2 will refer to DI-type or D2-type receptors rather than specific DI or D2 
receptor subtypes. Currently, a number of drugs are available that are relatively 
selective to either the DI-type or the D2-type receptor families. However, few drugs 
are available that are sufficiently selective for individual receptors within either family. 
Over the past decade, many researchers have focused their attention on 
discovering how different dopamine receptor types are involved in mediating the 
development of behavioral sensitization to psychostimulant drugs. Conceptualizing 
the role of various receptor sub-types may be important to the development of 
psychotherapeutic drugs with fewer side effects. In addition, an understanding of the 
involvement of these receptors in the development of behavioral sensitization may 
allow more effective methods of treating drug abuse to be developed. 
III. Dopamine Antagonists and Behavioral Sensitization to Apomorphine and 
Amphetamine: 
5 
Most drugs that induce behavioral sensitization, either directly ( e.g. 
apomorphine) or indirectly ( e.g. cocaine, amphetamine) result in an increased 
stimulation of both dopamine D1 and D2 receptor subtypes. One approach to study 
the involvement ofindividual receptor subtypes in the development of sensitization has 
been to administer a drug that selectively blocks or antagonizes a particular receptor 
concurrently with a psychostimulant drug. Most of the research using this strategy 
suggests that repeated stimulation ofD I receptors is critical to the development of 
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sensitization. For example, the development of behavioral sensitization to 
amphetamine is prevented by the co-administration of the selective D 1 antagonist, 
SCH-23390 (Stewart & Vezina, 1989). In contrast, co-administration of D2 
dopamine receptor antagonists ( e.g. sulpiride, pimozide, metoclopromide, or RO-22-
25 86) does not block behavioral sensitization to amphetamine (Drew & Glick, 1990; 
Stewart & Vezina, 1989; Vezina & Stewart, 1989). Similarly, the development of 
behavioral sensitization to the direct D l/D2 agonist apomorphine is also prevented by 
the co-administration of dopamine D 1, but not D2 receptor antagonists (Mattingly, 
Rowlett, Graff & Hatton, 1991). Taken together, these findings suggest that Dl 
receptor stimulation mediates the development of sensitization. 
IV. Dopamine Agonists and Behavioral Sensitization: 
In addition to using selective dopamine antagonists, researchers have also used 
drugs that directly and selectively activate a particular subfamily of dopamine 
receptors to study receptor mechanisms mediating the development of behavioral 
sensitization. Based upon the dopamine antagonist studies discussed previously, it 
would be predicted that the repeated stimulation of dopamine D 1-type, but not D2-
type, receptors would result in the development of behavioral sensitization. The 
results of these selective agonist studies, however, indicate that receptor involvement 
in mediating the development of sensitization is more complex than initially conceived. 
For example, the acute administration of the selective dopamine Dl-type receptor 
agonist, SKF 3 83 93, inhibits locomotor activity in rats, and this inhibition does not 
change with repeated daily treatments (Mattingly, Rowlett, & Lovell, 1993). On the 
surface, this finding appears inconsistent with the view that DI receptor stimulation is 
responsible for sensitization. However, numerous studies have indicated that 
dopamine DI and D2 receptors interact and that many dopamine-mediated behaviors 
are not expressed unless both receptor subtypes are stimulated (White, 1987). 
Consistent with this view, rats previously treated chronically with SKF 38393 display 
cross-sensitization to the activating effect of the direct-acting Dl/D2 dopamine 
receptor agonist apomorphine (Mattingly et al., 1993). Thus, consistent with the 
antagonist findings, repeated stimulation of dopamine DI-type receptors does appear 
to induce a sensitized response. This sensitized response, however, is only expressed 
when both DI and D2 receptors are activated (Mattingly et al., 1993). 
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As mentioned, based upon the antagonist findings, it would be predicted that 
repeated stimulation of dopamine D2-type receptors should not result in the 
development of behavioral sensitization. In contrast to this prediction, numerous 
studies have demonstrated that the repeated administration of the dopamine D2-type 
agonist, quinpirole induces sensitization (Mattingly et al., 1993; Szechtman, 
Talangbayan, & Eilam, 1993), and cross-sensitization to apomorphine (Mattingly et 
al., 1993). Moreover, the D2-type agonist bromocriptine also produces sensitization 
with repeated administration (Hoffman & Wise, 1992). These findings appear to be in 
direct conflict with the antagonist studies discussed previously indicating that D2 
receptor stimulation is not necessary for the development of sensitization to either 
apomorphine or amphetamine (Drew & Glick, 1990; Stewart & Vezina, 1989; Vezina 
& Stewart, 1989). However, subsequent research indicated that the development of 
sensitization the DZ-type agonists, quinpirole and bromocriptine, can be prevented 
with concurrent treatments with drugs that block DI-type receptors (Mattingly et al., 
1993; Wise & Carlezon, 1994). These latter findings suggest that D2 receptor 
stimulation induces sensitization indirectly through DI receptors. Together with the 
antagonist findings, the selective agonist results suggest that although dopamine D2 
receptor stimulation may contribute to the development of behavioral sensitization, 
repeated dopamine DI receptor stimulation is both necessary and sufficient for the 
induction of behavioral sensitization (Mattingly et al., 1993). 
V. Dopamine Receptor Involvement in Cocaine-Induced Behavioral Sensitization: 
It is generally accepted that nearly all drugs that directly or indirectly stimulate 
dopamine receptors. induce behavioral sensitization with repeated stimulation (Kalivas 
& Stewart, 1991; Robinson & Becker, 1986; Robinson & Berridge, 1993). This has 
led many researchers to conclude that sensitization is a unitary process mediated by 
common mechanisms within the dopaminergic system. The research discussed 
previously with selective dopamine receptor agonists and antagonists along with work 
with amphetamine and apomorphine, collectively suggests that a critical factor in the 
development of sensitization to all drugs is the repeated stimulation of dopamine D 1-
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type receptors. For the most part, sensitization research with cocaine has been 
consistent with this view. For example, White and colleagues have demonstrated that 
repeated cocaine treatments result in a transient subsensitivity of dopamine D2 
autoreceptors, and a long-lasting increase in the sensitivity of dopamine D 1 receptors 
in the nucleus accumbens (Henry & White, 199l;White, 1996). These 
electrophysiological findings, of course, are consistent with the conclusions drawn 
from previous research with amphetamine and apomorphine (Drew & Glick, 1990; 
Vezina & Stewart, 1989; Stewart & Vezina, 1989). However, recent research which 
has attempted to block the development of cocaine-induced sensitization with selective 
dopamine antagonists has been inconsistent with these findings. For example, 
Mattingly and colleagues were unable to prevent the development of sensitization to 
cocaine with the selective dopamine DI-type receptor antagonist, SCH 23390 or the 
D2-type antagonist, sulpiride (Mattingly, Hart, Lim & Perkins, 1994; Mattingly, 
Rowlett, Ellison & Rase, 1996). Similar findings have also been reported using mice 
(Kurihara & Uchihashi, 1993). These antagonist findings suggest that, unlike other 
dopamine agonists such as amphetamine and apomorphine, stimulation of dopamine 
DI-type receptors is not critical to the development of sensitization to cocaine. 
Moreover, these discrepant results with cocaine suggest that the development of 
behavioral sensitization to dopamine agonists may not be mediated by common 
neurochemical mechanisms. 
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Although selective dopamine antagonists are ineffective in preventing the 
development of cocaine-induced behavioral sensitization, a recent study has found that 
high doses of the moderately selective dopamine D2-type antagonist, haloperidol, does 
prevent the development of cocaine-induced behavioral sensitization (Mattingly et al., 
1996). This finding is perplexing because highly selective D2-type antagonists do not 
block the induction of sensitization to cocaine. However, since a very high dose of 
haloperidol was used, it is possible that at this dose both DI and D2-type receptors 
were antagonized (Mattingly et al., 1996). If so,. then this would suggest that cocaine-
induced behavioral sensitization may develop through the repeated stimulation of 
either D 1 or D2-type receptors. Thus, blocking sensitization to cocaine would require 
simultaneously blocking both receptor subtypes. It should be noted, however, that in 
addition to blocking dopamine receptors, haloperidol is also an antagonist at serotonin 
receptors and has a high affinity for sigma receptors (O'Dell et al., 1990; Quiron et al., 
1992). Consequently, the exact mechanisms responsible for haloperidol's effectiveness 
in preventing cocaine-induced sensitization remain unclear. 
VII. Purpose of Present Study: 
As discussed above, the development of sensitization to cocaine appears to be 
mediated differently from other dopamine agonists. Unlike sensitization to 
amphetamine and apomorphine, which appears to be mediated exclusively by 
stimulation of dopamine D 1 receptors, it appears that cocaine-induced sensitization 
L 
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may develop through the repeated stimulation of either dopamine receptor subtype. 
The purpose of the present study, therefore, was to test this latter hypothesis by 
determining whether cocaine-induced behavioral sensitization could be prevented by 
selectively blocking both DI and D2 receptors concurrently. Consequently, groups of 
rats were repeatedly given either cocaine or vehicle in combination with a cocktail of 
the DI antagonist, SCH 23390 and the D2 antagonist, eticlopride or vehicle. 
Following this chronic pretreatment phase, all rats were given a challenge injection of 
cocaine alone to test for sensitization. If the development of cocaine-induced 
behavioral sensitization is mediated by dopamine receptors, then the combination of 





Forty-eight male Wistar albino rats were obtained from Harlan Sprague-
Dawley, Inc. Indianapolis, Indiana. The rats weighed between 250-300g prior to 
testing. The rats were housed individually in standard wire-mesh cages in a 
temperature-controlled colony room with a 12 hr light-dark cycle. All testing was 
conducted during the light phase of the cycle. The rats were housed in the colony 
room for at least one week prior to the beginning of the experiment. During this time, 
each rat was weighed and handled for five min every other day. All rats had food and 
water available ad libidum. 
Apparatus 
Activity measures were taken in four square Med-Associates open field test 
chambers (Med-Associates model OFA-163, see Figure 1). These chambers were 
approximately 41 x 41 cm., and equipped with a 16 x 16 array of infrared photocell 
beams positioned 2.5 cm. above the floor and a single array of 16 photocells mounted 
10 cm. above the floor. A clear cylindrical acrylic chamber was positioned inside the 
outer square chamber. Output from each individual photocell array was connected to 
a Gateway 2000 (PS-75) microcomputer through a Med-Associates interface, located 
in an adjacent room. Using Med-Associates software, the following measures were 
13 






Figure 1. Med-Associates locomotor activity testing chambers. 
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The following drugs were dissolved daily in distilled H20: cocaine 
hydrochloride, eticlopride and SCH 23390. All drugs were injected subcutaneous 
(S.C.) or intraperitoneal (I.P.) in a volume of I ml/kg. All drug dosages were 
calculated based upon salt weight of the drug. Control injections were given using the 
same vehicle, route of administration, and volume as the corresponding drug injection. 
Design & Procedure 
The design of the experiment was a 2 x 2 factorial design, combining two 
antagonist doses and two cocaine doses. There were 12 rats per group and all rats 
were randomly assigned and counterbalanced within the 4 pretreatment groups. A 
summary of the experimental design is shown below in Table I and the 
counterbalancing procedure is depicted in Table 8, Appendix B. 
Table I 
Experimental Design 
Pretreatment groups (2 X 2 Factorial Design) 
Second injection (I.P.) 





SE-C (N=12) SE-V (N=l2) 
V-C (N=l2) V-V (N=l2) 
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The experiment was divided into two phases: a pretreatment phase, and a 
cocaine challenge test. During the pretreatment phase each rat was first injected S.C. 
with the selective DI dopamine antagonist SCH-23390 (0.10 mg/kg) and the selective 
dopamine D2 antagonist eticlopride (0.10 mg/kg) in combination or vehicle. Twenty-
five min later each rat was injected I.P. with cocaine (15 mg/kg), or an equivalent 
volume of vehicle. Five min after the cocaine injection, the rats were placed in the 
activity chambers for 60 min and tested for locomotor activity. This pre-treatment 
phase was repeated for four days. 
Twenty-four hours after the pre-treatment phase, all rats were first given a 
vehicle injection, S.C., and 25 min later, subsequently administered a challenge 
injection of cocaine (IO mg/kg I.P.) to test for behavioral sensitization. 
Data Analysis 
Statistical tests included mixed-factor analyses of variance with drug treatment 
conditions as between-groups factors and activity test sessions and blocks within 
sessions as repeated measures. These analyses were supplemented, when appropriate, 
with Newman-Keuls post hoc tests. 





The mean distance traveled in cm for each of the four pretreatment groups for 
the four 60 min pretreatment sessions is depicted in Figure 2, and the within session 
activity of the four pretreatment groups on Day 1 through Day 4 is depicted in Figure 
3. A mixed factor analysis of variance was performed on the mean distance traveled 
data with drug treatment conditions as between-groups factors and activity test 
sessions and blocks within sessions as repeated measures (see Appendix A, Table 2). 
As may be seen in Figure 2, rats treated with the antagonist combination (i.e., 
Sch/Etic-Vehicle, Sch/Etic-Cocaine groups) were significantly less active than the 
vehicle control rats, [antagonist effect: E(l, 44) = 200.35, 11 < .0001]. Although rats 
treated with only cocaine (i.e., Vehicle-Cocaine) were significantly more active than 
the vehicle control rats (i.e., Vehicle-Vehicle), cocaine did not significantly increase 
the activity of rats concurrently treated with the antagonist combination [ cocaine 
effect: E(l, 44) = 83.43, 11 < .0001; Antagonist x Cocaine interaction: F:(1, 44) = 
82.22, 11 < .0001]. That is, the antagonist pretreatment completely blocked the acute 
activating effect of cocaine on each day. As shown in Figure 3, the activity of the 
Vehicle-Cocaine and the Vehicle-Vehicle groups decreased across the four 15 min 
blocks within each 60 min session, whereas the activity of the two antagonist groups 
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remained consistently low across blocks, [block effect: E(3, 132) = 219.12, .Q < .0001; 
Antagonist x Block interaction: E(3, 132) = 221.12, .Q < .0001; Cocaine x Block 
interaction: E(3, 132) = 52.14, .Q < .0001; Antagonist x Cocaine x Block interaction: 
E(3, 132) = 52.73, .Q < .0001]. Although the activity of rats treated with only cocaine 
tended to increase across days, this increase was not significant, [Cocaine x Day 
interaction: E(3, 132) = 1.67, Q > .05]. Likewise, the activity of the other groups did 
not significantly change across days, as neither the day effect nor any of the 
interactions including day as a factor were significant (see Appendix A, Table 2). 
Stereotypic Counts: 
The mean number of stereotypic counts for each of the four pretreatment 
groups for the four 60 min pretreatment sessions is depicted in Figure 4, and the 
within session activity of the four pretreatment groups on Day 1 through Day 4 is 
depicted in Figure 5. A mixed factor analysis of variance was performed on the 
stereotypic data with drug treatment conditions as between-groups factors and activity 
test sessions and blocks within sessions as repeated measures ( see Appendix A, Table 
3). 
As may be seen in Figure 4, the results for the stereotypic count data are 
similar to those obtained for the distance traveled data. That is, rats treated with the 
antagonist combination (i.e., Sch/Etic-Vehicle, Sch/Etic-Cocaine groups) were 
significantly less active than the vehicle control rats, [antagonist effect: E(l, 44) = 
489.21, .Q < .001]. Although rats treated with only cocaine (i.e., Vehicle-Cocaine) 
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were significantly more active than the vehicle control rats (i.e., Vehicle-Vehicle), 
cocaine did not significantly increase the activity of rats concurrently treated with the 
antagonist combination [cocaine effect: l:(1, 44) = 100.89, rr < .001; Antagonist x 
Cocaine interaction: E(l, 44) = 102.60, rr < .0001]. That is, the antagonist 
pretreatment completely blocked the acute activating effect of cocaine on each day. 
As may be seen in Figure 5, the activity of the Vehicle-Cocaine and Vehicle-Vehicle 
groups decreased across the four 15 min blocks within each 60 min session, whereas 
the activity of the Sch/Etic-Vehicle and Sch/Etic-Cocaine groups remained 
consistently low across blocks [block effect: E(3, 132) = 168.19, rr < .0001; 
Antagonist x Block interaction: E(3, 132) = 152.57, rr < .0001; Cocaine x Block 
interaction: E(3, 132) = 10.32, rr < .0001; Antagonist x Cocaine x Block interaction: 
E(3, 132) = 10.82, rr < .0001]. Although the activity of rats treated with only cocaine 
tended to increase across days, this increase was not significant, [Cocaine x Day 
interaction: E < 1.00]. 
Rears: 
Similar mixed factor Anovas were performed on the vertical activity or rearing 
data (see Appendix A, Table 4). The mean number of rears for the four pretreatment 
groups over the four 60 min sessions is depicted in Figure 6. 
Again, the results for the rearing data are similar to the distance traveled and 
stereotypic data. As may be seen in Figure 6, That is, rats treated with the antagonist 
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active than the vehicle control rats, [antagonist effect: E(l, 44) = 93.81, ll. < .001]. 
Although rats treated with only cocaine (i.e., Vehicle-Cocaine) were significantly more 
active than the vehicle control rats (i.e., Vehicle-Vehicle), cocaine did not significantly 
increase the activity of rats concurrently treated with the antagonist combination 
[cocaine effect: E(l, 44) = 28.93, ll. < .001; Antagonist x Cocaine interaction: E(l, 44) 
= 28.62, Jl. < .0001]. That is, the antagonist pretreatment completely blocked the acute 
activating effect of cocaine on each day. Figure 7 displays the rearing behavior of the 
four pretreatment groups across blocks of 15 min during the four pretreatment 
sessions. As shown in Figure 7, the activity of the Vehicle-Cocaine and Vehicle-
Vehicle groups decreased across the four 15 min blocks within each 60 min session, 
whereas the activity of the Sch/Etic-Vehicle and Sch/Etic-Cocaine groups remained 
consistently low across blocks [block effect: E(3, 132) = 138.03, ll. < .0001; 
Antagonist x Block interaction: E(3, 132) = 138.69, ll. < .0001; Cocaine x Block 
interaction: E(3, 132) = 14.40, Jl. < .0001; Antagonist x Cocaine x Block interaction: 
E(3, 132) = 14.61, Jl. < .0001]. Although the activity of rats treated with only cocaine 
tended to increase across days, this increase was not significant, [Cocaine x Day 
interaction: E(3, 132) = 1.21, ll. > .05]. Likewise, the activity of the other groups did 
not significantly change across days, as neither the day effect nor of the interactions 
including day as a factor were significant (see Appendix A, Table 4). 
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A mixed factor analysis of variance was performed on the mean distance 
traveled data with drug treatment conditions as between-groups factors and blocks 
within sessions as a repeated measure (see Appendix A, Table 5). The mean distance 
traveled for the four pretreatment groups on the 60 min cocaine challenge test is 
depicted in Figure 8 and the within session activity of the groups is presented in Figure 
9. As may be seen in Figure 8, overall, rats pre-exposed to cocaine for four days 
were significantly more active after the cocaine challenge injection than rats receiving 
cocaine for the first time [ cocaine effect: E(l, 44) = 12.15, I).= .00 I], particularly on 
the first three 15 min time blocks [cf Figure 9; block effect: E(3, 132) = 199.30, P. < 
.0001; Cocaine x Block interaction: E(3, 132) = 8.85, I).< .0001). More important, 
this cocaine pretreatment effect was not affected by concurrent antagonist treatments 
[Antagonist x Cocaine interaction: E < 1.00; Antagonist x Cocaine x Block interaction: 
E < I. 00). In fact, rats treated with the antagonist combination were significantly 
more active on the cocaine challenge test than rats pretreated with only vehicle 
[antagonist effect: E(!, 44) = 14.66, I).< .001). Thus, rather than blocking the 
development of behavioral sensitization to cocaine, concurrent treatment with the 
antagonist combination appeared to increase subsequent behavioral sensitivity to 
cocaine. 
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The mean stereotypic counts for the four pretreatment groups during the 60 
min cocaine challenge test are shown in Figure 10 and the within session stereotypic 
activity of the four pretreatment groups is displayed in Figure 11. As may be seen in 
Figure 10, overall, rats pretreated for four days with the antagonist combination were 
significantly more responsive to the cocaine challenge injection than, rats that pre-
exposed to cocaine or vehicle only [antagonist effect: E(l, 44) = 16.69, !l. < .0001]. As 
shown in Figure 11, however, this effect was greater on blocks 3 and 4 than on blocks 
I and 2, as the vehicle pretreated groups (Vehicle-Vehicle, Vehicle-Cocaine) 
stereotypy scores decreased across blocks at a greater rate than did the antagonist 
pretreated groups (Sch/Etic-Vehicle, Sch/Etic-Cocaine) [block effect: E(3, 132) = 
114.09, !l. < .0001; Antagonist x Block interaction: E(3, 132) = 9.89, !l. < .0001]. 
More important, as may be seen in Figures 10 and 11, rats treated with cocaine did 
not display an increase in cocaine-induced stereotypy [ cocaine effect: E < 1.00; 
Cocaine x Block interaction: E < 1.00] (see Appendix A, Table 6). That is, behavioral 
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Figure 10. Mean stereotypic count(± SEM) after a challenge injection of cocaine (10 mg/kg) 
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BLOCKS OF 15 MINUTES 
' Figure 11. Mean stereotypic count (± SEM)after a challenge injection of cocaine 
(10 mg/kg) for each of the four pretreatrrent groups across the four 
15 min blocks within the 60 min session.· 
Rears: 
The mean number of rears for the four pretreatment groups following a 
challenge injection of cocaine are shown in Figure 12, and the within session rearing 
activity of the pretreatment groups is depicted in Figure 13. As may be seen, the 
antagonist pretreatment groups were significantly more responsive to the cocaine 
challenge on day five than vehicle or cocaine pretreatment groups [antagonist effect: 
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E(l, 44) = 16.86, 12 < .001], particularly on the first three 15 min time blocks [cf. 
Figure 13; block effect: E(3, 132) = 102.24, 12 < .0001; Antagonist x Block interaction: 
E(3, 132) = 4.51, 12 < .01] Although cocaine pretreatment did not result in an overall 
increase in rearing activity [cocaine effect: E(l,44) = 2.63, 12 > .05], rats pre-exposed 
to cocaine did display significantly greater rearing activity on the first 15 min time 
block compared to the vehicle pretreated rats [Cocaine x Block interaction: E(3,132) = 
7.70, 12 < .0001]. Thus, similar to the results using distance traveled as a behavioral 
measure, these data suggest that pretreatment with cocaine produced sensitization to 
cocaine-induced rearing behavior, and this effect was not blocked by concurrent 
treatment with the antagonist combination. 
500 
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Figure 12. Mean number of rears (±SEM) after a challenge injection of cocaine (10 mg/kg) 
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Figure 13. Mean number of rears (±SEM) after a challenge injection of cocaine (10 mg/kg) 
for each of the four pretreatment groups across the four 15 min blocks within the 
60 min session. 
CHAPTER4 
DISCUSSION 
I. Behavioral Sensitization to Cocaine: 
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Behavioral sensitization is defined as a progressive increase in behavioral 
sensitivity to a drug as a result ofrepeated administration. Depending upon design, 
two different methods have been used to measure the development of behavioral 
sensitization. One method has been to demonstrate a progressively greater behavioral 
effect of a drug with each succeeding administration. For example, numerous studies 
have demonstrated that the locomotor-activating effects of the direct dopamine 
agonist, apomorphine increase with each succeeding administration CD,amianopoulos & 
Carey, 1993; Mattingly et al., 1988; Rowlett, Mattingly, & Bardo, 1991). An 
alternative method of measuring behavioral sensitization has been to compare the 
effects of a challenge injection of the drug in rats previously treated with the drug to 
those receiving the drug for the first time. If sensitization develops, then animals pre-
exposed to the drug should display a significantly greater behavioral response to the 
drug than animals receiving the drug for the first time. Numerous studies using 
apomorphine, cocaine, and amphetamine have demonstrated the development of 
behavioral sensitization in this way (Kalivas & Stewart, 1991; Martin-Iverson & 
Reimer, 1994; Robinson & Becker, 1986; Segal, 1975). 
In the present study, both methods of measuring behavioral sensitization were 
used with three different measures of motor behavior. Consistent with previous 
studies, rats previously treated with cocaine for four consecutive days displayed a 
significantly greater behavioral reaction to the cocaine challenge injection on Day 5 
than rats receiving cocaine for the first time (Mattingly et al., 1996; White, Joshi, 
Koeltzow & Hu, 1998). In contrast, rats pretreated with cocaine did not display a 
progressive between-session increase in activity across the four pretreatment days. 
This discrepancy between the two measures of sensitization has been noted before 
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( e.g., Martin-Iverson & Reimer, 1994). In the case of cocaine, sensitization has been 
most frequently observed after a challenge test, whereas between session increases in 
cocaine-induced activity are often not observed (Hooks, Jones, Smith, Neill & Justice, 
1991; Mattingly et al., 1994). One factor that may contribute to this discrepancy is the 
dose of cocaine used. For example, on the challenge test, a 10 mg/kg dose of cocaine 
was used, whereas in the pretreatment phase, a 15 mg/kg dose was used. It is possible 
that the higher dose of cocaine produced a ceiling effect with respect to activity. That 
is, at this dose, the acute activating effects of cocaine may have been too high to 
observe further increases in activity. By using a lower dose on the challenge test, 
differences in sensitivity may have been easier to observe. In fact, this was the 
rationale for using a lower dose for the challenge test. Although a lower dose could 
have been used during pretreatment to avoid a possible ceiling effect, the 15 mg/kg 
dose of cocaine has been shown to be the most effective dose for inducing maximum 
sensitization (Kalivas, Duffy, DuMars & Skinner, 1988). 
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It should be noted that behavioral sensitization to cocaine was observed on the 
challenge test for the distance traveled and rearing measures, but not for the stereotypy 
measure. Although a few studies have reported sensitization to cocaine using 
stereotypy (Henry & White, 1995; McCreary & Marsden, 1993), the vast majority of 
cocaine-sensitization studies have used horizontal locomotion and rearing as 
behavioral measures (Fontanna, Post, Weiss & Pert, 1993; Kalivas et al., 1988; 
Mattingly et al., 1994; Mattingly et al., 1996). Consistent with these findings, 
behavioral sensitization to apomorphine is also observed using horizontal locomotion, 
but not using stereotypy as a behavioral measure (Mattingly, Gotsick & Marin, 1988). 
A great deal of evidence suggests that stereotypic responses induced by dopaminergic 
agonists is mediated by increased stimulation of dopamine receptors in the nigrostriatal 
dopamine pathway, whereas the locomotor-activating effects of dopamine agonists are 
mediated by increased stimul_ation of the mesolimbic pathway (White, 1996). Ifso, 
then the current findings suggest that the development of behavioral sensitization to 
cocaine is mediated by alterations in the mesolimbic dopamine pathway. 
II. Antagonists Effects: 
As discussed previously, it has generally been assumed that the development of 
behavioral sensitization to cocaine requires the repeated intermittent stimulation of 
dopamine receptors (Henry & White, 1991; Kalivas & Stewart, 1991; Robinson & 
Becker, 1986; Robinson & Berridge, 1993). Consistent with this view, repeated 
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cocaine treatments have been shown to result in a transient subsensitivity of dopamine 
D2-type autoreceptors, and a long-lasting increase in the sensitivity of dopamine D 1-
type receptors (Henry & White,1991; White, 1996). These changes have been 
proposed to mediate the development of behavioral sensitization to cocaine and to 
occur as a result of the cocaine-induced increase in extracellular dopamine (Kalivas & 
Stewart, 1991; Robinson & Becker, 1986). This hypothesis would predict, however, 
that concurrent treatment with dopamine antagonists would block the development of 
behavioral sensitization to cocaine. Clearly, the present results are inconsistent with 
this view. 
In the present experiment, rats were pretreated with a combination of the 
selective DI-type antagonist, SCH 23390, and the selective D2-type antagonist, 
eticlopride prior to each daily cocaine treatment. This combined treatment greatly 
suppressed all indices oflocomotor activity and completely blocked the locomotor-
activating effects of cocaine. Thus, there appears to be no question that this drug 
cocktail effectively blocked dopamine receptors. Despite this antagonism, however, 
rats pretreated with the antagonist combination and cocaine were clearly 
supersensitive to the cocaine challenge injection. Thus, blocking both D 1- and D2-
type receptors did not block the development of sensitization to cocaine. 
This finding is consistent with previous work from our laboratory, which 
indicated that the selective DI- and D2-type dopamine antagonists administered alone 
are ineffective in preventing the development of cocaine-induced behavioral 
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sensitization (Mattingly et al., 1994; Mattingly et al., 1996). Other researchers have 
also failed to prevent the development of behavioral sensitization to cocaine using 
other selective dopamine antagonists with mice (Kurihara & Uchihashi, 1993). 
Moreover, this antagonist combination was recently shown to be ineffective in 
blocking the development of cocaine-induced behavioral sensitization in a study using 
a non-associative procedure and longer withdrawal intervals (White et al., 1998). 
Taken together, these findings suggest that the development of behavioral sensitization 
to cocaine does not require the repeated stimulation of dopamine receptors. 
Curiously, it has been reported that concurrent treatments with high doses of 
the relatively non-selective dopamine antagonist, haloperidol, does block the 
development of cocaine-induced behavioral sensitization using a procedure similar to 
that used in the current study (Mattingly et al., 1996). Moreover, haloperidol has been 
reported to block the development of sensitization to cocaine using a novel one-
exposure treatment paradigm (Weiss, Post, Pert, Woodward, & Murman, 1989). As 
noted earlier, since very high doses of haloperidol were used in these studies, it was 
assumed that haloperidol was effective because of a combined blockade of both D l-
and D2-type receptors (cf., Mattingly et al., 1996). However, the current results are 
inconsistent with this interpretation. At present, the mechanisms mediating the 
effectiveness ofhaloperidol in blocking the development of sensitization to cocaine are 
unclear. Nonetheless, besides blocking dopamine receptors, haloperidol also has 
antagonistic actions at serotonergic receptors and has a high affinity for sigma 
receptors (O'Dell et al., 1990; Quiron et al., 1992). Thus, these non-dopaminergic 
effects of haloperidol may be involved in some way in the development of behavioral 
sensitization to cocaine. Indeed, cocaine is a potent inhibitor of serotonin re-uptake 
and alteration in the serotonergic neurotransmitter system have been reported 
following repeated cocaine administration (Ritz, Cone & Kuhar, 1990). 
III. Antagonist-Induced Sensitivity to Cocaine: 
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As discussed previously, selective dopamine Dl-type receptor antagonists have 
been reported to block the development of sensitization to other dopamine agonists 
such as apomorphine, amphetamine, bromocriptine, and quinpirole (Drew & Glick, 
1990; Mattingly et al., 1991; Mattingly et al., 1993; Wise & Carlezon, 1994). Thus, 
the inability ofDl-type antagonists to block cocaine-induced sensitization was 
unexpected since most researchers have assumed that sensitization to these drugs 
involved a common dopaminergic mechanism. Another intriguing finding of the 
present study is the increased sensitivity to cocaine observed in animals that were 
pretreated with only the antagonist combination (cf., Figure 8.). A similar antagonist-
induced increase in subsequent sensitivity to cocaine has recently been observed 
following brief repeated treatments with haloperidol, SCH 23390, sulpiride, and YM-
09151-2 (Kurihara & Uchihashi, 1993; Mattingly et al., 1994; White, 1998). 
Moreover, repeated treatments with the mixed dopamine antagonist cis-(Z)-
flupentixol, has been reported to increase subsequent sensitivity to cocaine in a self-
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administration paradigm (Peltier & Emmett-Oglesby, 1994). Thus, brief treatments 
with dopamine antagonists appear to enhance sensitivity to both the locomotor-
activating and the rewarding effects of cocaine. These findings are surprising because 
repeated dopamine antagonist treatments do not increase subsequent sensitivity to 
other dopamine agonists (Mattingly et al., 1991; Stewart & Vezina, 1989; Vezina & 
Stewart, 1989). Taken together, these findings also suggest that the development of 
sensitization to cocaine may involve a unique neurochemical mechanism. 
At present, the neurochemical mechanism mediating this antagonist-induced 
increase in sensitivity to cocaine is unclear. Although changes in dopamine receptors 
may be involved, antagonist-induced dopamine receptor up-regulation is usually found 
only after several weeks of antagonist treatments (Creese & Chen, 1985; Hess, Albers, 
Le & Creese, 1986). Moreover, as noted above, the locomotor-activating effects of 
the direct dopamine agonist, apomorphine, are not enhanced after similar antagonist 
treatments (Mattingly et al., 1991). Despite the lack of observable morphological 
changes in dopamine receptors, some recent evidence suggests brief antagonist 
treatments might produce some functional changes in dopamine receptors (White et 
al., 1998). For example, after brief treatments with the selective dopamine DI-type 
antagonist SCH 23390, neurons with dopamine receptors in the nucleus accumbens 
display an augmented electrophysiological response to dopamine (White et al., 1998). 
Although the basis for this increased responsiveness is unknown, it could play a role in 
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the antagonist-induced increase in behavioral sensitivity to cocaine. Clearly, additional 
research is warranted to determine the exact basis for this effect. 
IV. Summary and Conclusions: 
The present results clearly indicate that behavioral sensitization develops to 
cocaine after brief treatments. More important, the current findings indicate that the 
development of sensitization to cocaine is not prevented by concurrently blocking both 
DI-type and D2-type dopamine receptors. This finding suggests that other 
neurochemical systems, besides dopaminergic, may be involved in the development of 
sensitization to cocaine. Since sensitization to other psychostimulant drugs such as 
amphetamine and apomorphine can be prevented with concurrent treatments with 
mixed and selective DI-type dopamine antagonists, the current findings suggest that 
cocaine-induced behavioral sensitization may be mediated by unique neurochemical 
mechanisms. Moreover, the current results indicate that brief treatments with 
dopamine antagonists alone increase subsequent sensitivity to cocaine. This finding 
also contrasts with sensitization studies with other dopamine agonists, and further 
suggests that the mechanisms mediating cocaine-induced behavioral sensitization differ 
from those of other psychostimulant drugs. 
The current results may have significant implications for the treatment of drug 
abuse. As noted previously, one of the main factors underlying the high relapse rate 
among cocaine abusers in withdrawal is the intense and persistent craving ( cf., 
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Robinson & Berridge, 1993). Like sensitization, craving is known to increase in 
intensity and persistence with repeated drug exposure. Thus, drugs are needed for 
treatment which will block or reverse craving, and which are not reinforcing when 
administered alone. Moreover, the ideal drug will also decrease subsequent sensitivity 
to cocaine. Assuming that behavioral sensitization is a valid model of craving, the 
present results suggest that the use of dopamine antagonists would be an ineffective 
treatment for cocaine addiction. First, these agents do not block the development of 
behavioral sensitization, and therefore, according to the model, would not prevent the 
further development of craving if taken concurrently with cocaine. More important, 
since these drugs increase subsequent sensitivity to cocaine, repeated treatments with 
these agents during withdrawal may actually increase craving in the absence of the 
drug. Clearly, additional research is necessary to help define precisely the 
neurochemical alterations induced by repeated cocaine exposure before the 
appropriate drug treatments can be developed. 
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Table 2 
Summary of Analysis of Variance Performed on Mean 
Distance Traveled : Pretreatment Days 1-4 
Source df MS F nu2 
Between Groups 
Antagonist (A) 1 205683542 200.35*** .82 
Cocaine (C) 1 85652845 83.43*** .65 
Axe 1 84411477 82.22*** .65 
Error 44 1026608 
Within Groups 
Day (D) 3 354268.4 0.63 
AxD 3 371565.9 0.66 
CxD 3 944127.9 1.67 
AxCxD 3 983614.0 1.74 
Error 132 564925 
Block (B) 3 21050114 219.12*** .83 
AxB 3 21241682 221.12*** .83 
CxB 3 5008374 52.14*** .54 
AxCxB 3 5065515 52.73*** .55 
Error 132 96065 
DxB 9 118099.2 1.76 
AxDxB 9 124595.9 1.85 
CxDxB 9 101167.1 1.50 
AxCxDxB 9 100432.1 1.49 




Summary of Analysis of Variance Performed on Mean 
Stereotypic Counts: Pretreatment Days 1-4 
Source df MS F nu2 
Between Groups 
Antagonist (A) 1 753342610 489.21 *** .92 
Cocaine (C) 1 155356243 100.89*** .70 
AxC 1 158001218 102.60*** .70 
Error 44 1539925 
Within Groups 
Day (D) 3 1678052.1 1.97 
AxD 3 440395.7 0.52 
CxD 3 438940.7 0.52 
AxCxD 3 774374.1 0.91 
Error 132 850206 
Block (B) 3 29372554 168.19*** .79 
AxB 3 26644924 152.57*** .78 
CxB 3 1802043 10.32*** .19 
AxCxB 3 1889990 10.82*** .20 
Error 132 174641 
DxB 9 338584.5 3.30** .07 
AxDxB 9 370277.3 3.61 ** .08 
CxDxB 9 123611.8 1.21 
AxCxDxB 9 149978.7 1.46 





Summary of Analysis of Variance Performed on Mean 
Number of Rears: Pretreatment Days 1-4 
Source df MS F nu2 
Between Groups 
Antagonist (A) 1 787328.26 93.81 *** .68 
Cocaine (C) 1 242820.75 28.93*** .40 
AxC 1 240196.26 28.62*** .39 
Error 44 8392.77 
Within Groups 
Day (D) 3 298.8368 0.14 
AxD 3 246.1753 0.11 
CxD 3 2601.1910 1.21 
AxCxD 3 2726.5295 1.27 
Error 132 2148.44 
Block (B) 3 90489.89 138.03*** .76 
AxB 3 90921.55 138.69*** .76 
CxB 3 9440.20 14.40*** .25 
AxCxB 3 9575.41 14.61 *** .25 
Error 132 655.58 
DxB 9 1019.410 1.13 
AxDxB 9 1032.290 1.14 
CxDxB 9 1463.616 1.62 
AxCxDxB 9 1484.857 1.64 




Summary of Analysis of Variance Performed on Mean 
Distance Traveled: Cocaine Challenge Day 5 
Source df MS F nu2 
Between Groups 
Antagonist (A) 1 18530931 14.66** .25 
Cocaine (C) 1 15357533 12.15** .22 
AxC 1 65300 0.05 
Error 44 1264380 
Within Groups 
Block (B) 3 37232750 199.30*** .82 
AxB 3 262863 1.41 
CxB 3 1654038 8.85*** .17 
AxCxB 3 100198 0.54 





Summary of Analysis of Variance Petfonned on Mean 
Stereotypic Count: Cocaine Challenge Day 5 
Source df MS F nu2 
Between Groups 
Antagonist (A) 1 18396061 16.69*** .28 
Cocaine (C) 1 1122867 1.02 
AxC 1 469360 0.43 
Error 44 1102296 
Within Groups 
Block (B) 3 21520558 114.09*** .72 
AxB 3 1866240 9.89*** .18 
CxB 3 168431 0.89 
AxCxB 3 118972 0.63 




Summary of Analysis of Variance Performed on Mean 
Number of Rears: Cocaine Challenge Day 5 
Source df MS F nu2 
Between Groups 
Antagonist (A) 1 87680.255 16.86** .28 
Cocaine (C) 1 13685.630 2.63 
AxC 1 1349.380 0.26 
Error 44 5201.75 
Within Groups 
Block (B) 3 93620.96 102.24*** .70 
AxB 3 4128.13 4.51 * .09 
CxB 3 7051.92 7.70*** .15 
AxCxB 3 904.12 0.99 









Squad# Subject# Pretreatment Group Chamber# 
1 1 Vehicle-Vehicle 1 
1 2 Vehicle-Cocaine 2 
1 3 SCH/Etic-Vehicle 3 
1 4 SCHIE tic-Cocaine 4 
2 5 SCH/Etic-Vehicle 1 
2 6 SCHIE tic-Cocaine 2 
2 7 Vehicle-Vehicle 3 
2 8 Vehicle-Cocaine 4 
3 9 Vehicle-Cocaine 1 
3 10 Vehicle-Vehicle 2 
3 11 SCH/Etic-Cocaine 3 
3 12 SCH/Etic-Vehicle 4 
4 13 SCHIE tic-Cocaine 1 
4 14 SCH/Etic-Vehicle 2 
4 15 Vehicle-Cocaine 3 
4 16 Vehicle-Vehicle 4 
5 17 Vehicle-Vehicle 1 
5 18 Vehicle-Cocaine 2 
5 19 SCH/Etic-Vehicle 3 
5 20 SCH/Etic-Cocaine 4 
6 21 SCH/Etic-Vehicle 1 
6 22 SCH/Etic-Cocaine 2 
6 23 Vehicle-Vehicle 3 
6 24 Vehicle-Cocaine 4 
7 25 Vehicle-Cocaine 1 
7 26 Vehicle-Vehicle 2 
7 27 SCH/Etic-Cocaine 3 
7 28 SCH/Etic-Vehicle 4 
8 29 SCH/Etic-Cocaine 1 
8 30 SCH/Etic-Vehicle 2 
8 31 Vehicle-Cocaine 3 
8 32 Vehicle-Vehicle 4 
9 33 Vehicle-Vehicle 1 
9 34 Vehicle-Cocaine 2 
9 35 SCH/Etic-Vehicle 3 
9 36 SCHIE tic-Cocaine 4 
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TABLE 8 (Continued) 
Squad# Subject# Pretreatment Group Chamber# 
10 37 SCH/Etic-Vehicle 1 
10 38 SCH/Etic-Cocaine 2 
10 39 Vehicle-Vehicle 3 
10 40 Vehicle-Cocaine 4 
11 41 Vehicle-Cocaine 1 
11 42 Vehicle-Vehicle 2 
11 43 SCHIE tic-Cocaine 3 
11 44 SCH/Etic-Vehicle 4 
12 45 SCHIE tic-Cocaine 1 
12 46 SCH/Etic-Vehicle 2 
12 47 Vehicle-Cocaine 3 
12 48 Vehicle-Vehicle 4 
